Listed as number three in pharma sales, GlaxoSmithKline has had some rough luck thanks in part to the diabetes drug Avandia, which has been pulled out of Europe and restricted in the U.S after global side effect concerns since 2007. The company cut its losses on the drug, writing off $233 million in supplies and eliminating its marketing efforts of the drug.

The company has racked up some charges against its earnings, including over $6 billion in the fourth quarter of 2010 from Avandia and marketing settlements. GSK settled 10,000 Avandia lawsuits for a combined $460 million. Also, the company hit number three on FiercePharma's Top Layoffs of 2010 list with 5,201 jobs lost. While other companies look towards more spinoffs, GSK has focused on emerging markets as its ticket to higher revenue. It purchased Laboratorios Phoenix in 2009 and China's MeiRui in 2010; the UK-based company said the impact of its layoffs would be masked by more job opportunities in Asia and South America.

In early 2011, GSK and Human Genome Sciences gained FDA approval for Benlysta, the first new lupus treatment in more than 50 years, and experts believe it could be a $3 billion to $5 billion worldwide sales heyday for the partnership. But the FDA denied an extended approval and a potential $1 billion in sales to GSK from the prostate drug Avodart. While the drug was effective against low-risk malignant tumors, it potentially heightened the risk of developing more aggressive tumors.

GSK spun off its HIV treatments into ViiV Healthcare in 2009, combining it with Pfizer's former R&D efforts in the field. ViiV markets Ziagen, Trizivir, Epzicom and abacavir as part of its suite of drugs for HIV/AIDS.

Tag:

GlaxoSmithKline

Latest Headlines

Latest Headlines

GSK's big, bad whooping cough vaccination campaign bares its teeth

The wolf who gobbled up Little Red Riding Hood's grandma has nothing on GlaxoSmithKline's new big bad wolf. The frightening star of a new marketing effort encouraging whooping cough vaccinations transfigures a grandmother's face while she cradles her newborn grandchild. Even GSK notes the ad may be "a bit unsettling" to some people.

GlaxoSmithKline and Purdue look to Apple's ResearchKit for R&D

ResearchKit, the technology Apple promises will transform the world's hundreds of millions of iPhones into handheld gatherers of clinical data, could become a viable tool in drug development, and two major drugmakers are working to integrated into clinical trials.

GSK working to build Apple's ResearchKit into its clinical trials

GlaxoSmithKline has revealed it is working to integrate Apple's ResearchKit into its clinical trials, setting it up to be one of the first drug developers to adopt the recently introduced platform. The Big Pharma sees the open-source research app as a useful tool for data collection.

Glaxo's HIV unit ViiV aims to steal share from Gilead before patents bite

GlaxoSmithKline's ViiV Healthcare stole the show in Q1, surpassing analyst expectations and prompting the pharma to hang on to the HIV drug business, canceling all plans for a potential spinoff. There's just one problem: ViiV may one day become a victim of its own success.

BMJ: Pfizer, Allergan antidepressants show no links to birth defects

Antidepressants have long been linked to an increased risk of birth defects, with companies fighting claims that the meds cause serious issues in newborns if women take the drugs during pregnancy. Now, a new study published in the British Medical Journal shows that only some of the drugs turn up risks of birth defects, dealing a spate of good news to companies making the products.

Scientists dig up new evidence linking GSK's Pandemrix with narcolepsy

A team of Stanford University scientists think they have found a potential reason why GlaxoSmithKline's now-withdrawn flu shot Pandemrix was associated with a spike in narcolepsy cases.

New evidence strengthens narcolepsy link to GSK's Pandemrix

In 2013, scientists and governments estimated that there were close to 800 narcolepsy cases tied to GlaxoSmithKline's swine flu vaccine, Pandemrix. And now, a team of scientists at Stanford University believes they have discovered the link.

GSK's ViiV unit to work with China's Desano to make API of Tivicay for access use

The API of GlaxoSmithKline's HIV therapy Tivicay (dolutegravir) will be made in China by Shanghai-based Desano Pharmaceuticals under a deal with the British drug maker's ViiV Healthcare arm, according to a press release.

Sworn to end doc payments by 2016, GSK still shelled out $15M last year

In 2013, GlaxoSmithKline CEO Andrew Witty pledged to end doctor payments by 2016 as part of an effort to clean up the company's image. But so far, little has changed in that department.

More SCOTUS fallout: Appeals court revives Lamictal pay-for-delay fight against GSK, Teva

In the post- FTC v. Actavis  world, cash doesn't have to change hands for a pay-for-delay deal to fall afoul of antitrust law. That's becoming clear as court rulings pile up. And a new U.S. appeals court decision specifically addresses a branded drugmaker's agreement not to launch an authorized generic of its branded drug.